Characterization of an orally available respiratory syncytial virus L protein polymerase inhibitor DZ7487

作者全名："Guo, Qiuli; Qian, Jin; Zeng, Qingbei; Zhang, Lin; Zhu, Xuehua; Zheng, Jie; Chen, Kan; Liu, Enmei"

作者地址："[Guo, Qiuli] Peking Univ, Acad Adv Interdisciplinary Studies, Biomed X Ctr, Beijing 100871, Peoples R China; [Guo, Qiuli; Qian, Jin; Zeng, Qingbei; Zhang, Lin; Zhu, Xuehua; Zheng, Jie; Chen, Kan] Dizal Pharmaceut, Shanghai 201203, Peoples R China; [Liu, Enmei] Chongqing Med Univ, Dept Resp Dis, Childrens Hosp, Chongqing, Peoples R China"

通信作者："Guo, QL (通讯作者)，Peking Univ, Acad Adv Interdisciplinary Studies, Biomed X Ctr, Beijing 100871, Peoples R China.; Guo, QL (通讯作者)，Dizal Pharmaceut, Shanghai 201203, Peoples R China."

来源：AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH

ESI学科分类：BIOLOGY & BIOCHEMISTRY

WOS号：WOS:000988972900001

JCR分区：Q3

影响因子：1.7

年份：2023

卷号：15

期号：3

开始页：1680

结束页：1692

文献类型：Article

关键词：RSV; RdRp; DZ7487; L protein; oral; non-nucleoside

摘要："Objectives: Respiratory Syncytial Virus (RSV) is a leading cause of death and hospitalization among infants and young children. People with an immunocompromised status are also at risk for severe RSV infection. There is no specific treatment for RSV infection available. Ribavirin, an antiviral drug approved for severe lung infection by RSV, has shown limited clinical efficacies with severe side effects. Additionally, given the genetic variability of RSV genomes and seasonal change of different strains, a broad-spectrum antiviral drug is highly desirable. The RNA -dependent RNA polymerase (RdRp) domain is relatively conserved and indispensable for the replication of the virus genome and therefore serves as a potential therapeutic target. Previous attempts to identify an RdRp inhibitor have not been successful due to lack of potency or high enough blood exposure. DZ7487 is a novel orally available small molecule inhibitor specifically designed to target the RSV RdRp. Here we present our data showing that DZ7487 can potently inhibited all clinical viral isolates tested, with large safety margin predicted for human. Methods: HEp-2 cells were infected by RSV A and B. Antiviral activities were assessed by in vitro cytopathic effect assay (CPE) and Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). DZ7487 antiviral effects in lower airway cells were evaluated in A549 and human small airway epithelial cells (SAEC) cells. DZ7487 induced RSV A2 escape mutations were selected through continuous culture with increasing DZ7487 concentrations in the culture medium. Resistant mutations were identified by next generation sequencing and confirmed by recombinant RSV CPE assays. RSV infection models in both BALB/c mice and cotton rats were used to evaluate DZ7487 in vivo antiviral effects. Results: DZ7487 potently inhibited viral replication of all clinical isolates of both RSVA and B subtypes. In lower air-way cells, DZ7487 showed superior efficacy than the nucleoside analog ALS-8112. Acquired resistant mutation was predominantly restricted at the RdRp domain resulting asparagine to threonine mutation (N363T) of the L protein. This finding is consistent with DZ7487's presumed binding mode. DZ7487 was well tolerated in animal models. Unlike fusion inhibitors, which can only prevent viral infection, DZ7487 potently inhibited RSV replication before and after RSV infection in vitro and in vivo. Conclusions: DZ7487 demonstrated potent anti-RSV replication effect both in vitro and in vivo assays. It has the desired drug-like physical properties to be an effective orally available anti-RSV replication drug with broad spectrum."

基金机构：　

基金资助正文：